Spontaneous remission in canine myasthenia gravis: Implications for assessing human MG therapies

Neurology

Volumn 57, Issue 11, 2001, Pages 2139-2141

  Shelton, G Diane ^a   Lindstrom, Jon M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOG; IMMUNOTHERAPY; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; REMISSION;

EID: 0035846541     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.57.11.2139     Document Type: Article

References (10)

1. Canine and human myasthenia gravis autoantibodies recognize similar regions on the acetylcholine receptor
2. Acquired myasthenia gravis: What we have learned from experimental and spontaneous animal models
3. Autoimmunity in spontaneous myasthenia gravis in dogs
4. Treatment of myasthenia gravis. A call to arms
5. Myasthenia gravis: Recommendations for clinical research standards
6. The natural course of myasthenia gravis and effect of therapeutic measures
7. The treatment of patients with myasthenia gravis
8. Anti-acetylcholine receptor antibodies in D-penicillamine-associated myasthenia gravis
9. Penicillamine-induced myasthenia gravis: Effects of penicillamine on acetylcholine receptor
10. Acetylcholine receptors and myasthenia